GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Cash Flow from Others

Microba Life Sciences (ASX:MAP) Cash Flow from Others : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences Cash Flow from Others?

Microba Life Sciences's cash flow from others for the six months ended in Dec. 2023 was A$0.00 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.


Microba Life Sciences Cash Flow from Others Historical Data

The historical data trend for Microba Life Sciences's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microba Life Sciences Cash Flow from Others Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23
Cash Flow from Others
- -

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Others - - - - -

Microba Life Sciences Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Microba Life Sciences Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Microba Life Sciences's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Microba Life Sciences (ASX:MAP) Business Description

Traded in Other Exchanges
N/A
Address
324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome which includes delivering gut microbiome testing services globally to consumers, clinicians, and researchers. The company's segment includes Testing Services, and Research and Development.

Microba Life Sciences (ASX:MAP) Headlines

No Headlines